1 June 2011 in Pediatrics
OBJECTIVE: To fill gaps in crucial data needed for health and educational planning, we determined the prevalence of developmental disabilities in US children and in selected populations for a recent 12-year period. PARTICIPANTS AND METHODS: We used data on children aged 3 to 17 years from the 1997–2008 National Health Interview Surveys, which are ongoing nationally representative samples of US households. Parent-reported diagnoses of the following were included: attention deficit hyperactivity disorder; intellectual disability; cerebral palsy; autism; seizures; stuttering or stammering; moderate to profound hearing loss; blindness; learning disorders; and/or other developmental delays. RESULTS: Boys had a higher prevalence overall and for a number of select disabilities compared with girls. Hispanic children had the lowest prevalence for a number of disabilities compared with non-Hispanic white and black children. Low income and public health insurance were associated with a higher prevalence of many disabilities. Prevalence of any developmental disability increased from 12.84% to 15.04% over 12 years. Autism, attention deficit hyperactivity disorder, and other developmental delays increased, whereas hearing loss showed a significant decline. These trends were found in all of the sociodemographic subgroups, except for autism in non-Hispanic black children. CONCLUSIONS: Developmental disabilities are common and were reported in ∼1 in 6 children in the United States in 2006–2008. The number of children with select developmental disabilities (autism, attention deficit hyperactivity disorder, and other developmental delays) has increased, requiring more health and education services. Additional study of the influence of risk-factor shifts, changes in acceptance, and benefits of early services is needed.
1 June 2014 in Pediatrics
Newborn screening (NBS) began 50 years ago with the ability to screen for phenylketonuria from dried-blood spots and prevent long-term disability through dietary intervention. Now nearly all of the 4 million infants born in the United States are screened for a wide array of significant medical conditions by using dried-blood spots and point-of-care tests, leading to early diagnosis and treatment of more than 12 500 newborns each year. NBS is an unqualified public health success; it saves lives, prevents severe disability, and is a good use of limited health care dollars. NBS is not a test, but a complex system that includes the initial screen to identify infants with a high probability of having the condition, a follow-up diagnostic test to identify true cases, and the ongoing treatment of the condition. To make this system efficient and effective requires several key players, including public health, primary and specialty care providers, and families. On this anniversary of NBS, we would like to share our reflections on these 3 perspectives, acknowledging that they capture only some of the important considerations and advances in NBS.
1 November 2005 in American Journal of Public Health
1 December 2012 in American Journal of Preventive Medicine
1 January 2005 in Thyroid®
A workshop entitled, "The Impact of Maternal Thyroid Diseases on the Developing Fetus: Implications for Diagnosis, Treatment, and Screening," was held in Atlanta, Georgia, January 12–13, 2004. This paper reports on the session that examined methods and criteria used for decisions in public health. For this session the following papers were presented: "Methods to Evaluate Scientific Evidence," "Criteria for Screening," and "Public Health Considerations." Development of evidence-based guidelines, strengthened by rigorous systematic reviews, will improve the quality, efficiency, and cost effectiveness of management of thyroid dysfunction among reproductive-age women. Maternal and fetal benefits that have been hypothesized to result from screening pregnant and pre-pregnant women for hypothyroidism include reduced incidences of peripartum maternal complications and fetal loss and optimization of fetal and neonatal neuropsychological development. Screening should be considered as the initial step in a comprehensive program that includes appropriate diagnostic and therapeutic interventions. The actual benefits and potential risks (i.e., iatrogenic thyrotoxicosis) of implementing a thyroid function screening program have not been demonstrated in a prospective randomized clinical trial or prospective cohort study. Consequently, it is difficult to develop consensus and secure resources for a comprehensive thyroid function screening and therapeutic intervention program in women who are or anticipate becoming pregnant. Marshalling support for performance of both a clinical trial and high-quality observational studies should be a high priority.
1 July 2005 in Journal of Communication Disorders